How the DEA and FDA will regulate psychedelic medicine
How the DEA and FDA will regulate psychedelic medicine
Business Trip, a podcast about psychedelic entrepreneurship
Welcome back to Business Trip, a podcast about psychedelic entrepreneurship! 🍄
In this week’s episode, we chat with Matt Zorn, an attorney at Yetter Coleman. Matt has expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA’s decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker’s psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley’s DEA case related to cannabis scheduling and research. He also writes the drug policy newsletter On Drugs.
In this episode, we discuss:
How psychedelic companies operate according with FDA and DEA guidelines
What psychedelic companies can do to increase their chance of approval
How drug scheduling works
Matt’s views about classic psychedelics vs. new chemical entities
Listen to the episode here, on Spotify or Apple Podcasts.
When you’re done listening, tweet at us @businesstripfm to share your thoughts!
About Us
Business Trip tells the story of the emerging industry of psychedelics. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re partners at PsyMed Ventures, advocates of the healing powers of psychedelic medicine and see a bright future ahead for the industry.
Thanks for listening,
💖 Know someone who would enjoy Business Trip?